EBV Blocks NOXA Induction Acknowledgments Author Contributions We would like to thank Gemma Kelly and Alan Rickinson for provision of Sal-BL, Oku-BL and BL2+E2KO cell lines and Paul Farrell and Martin Rowe for antibodies. Conceived and designed the experiments: MJA REW JY. Performed the experiments: JY EA. Analyzed the data: MJA JY REW. Contributed reagents/materials/analysis tools: EA. Wrote the paper: JY REW MJA. References 1. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757–768. 2. Bornkamm GW, Hammerschmidt W (2001) Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356: 437–459. 3. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328–1337. 4. Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt’s lymphoma. Nat Rev Microbiol 6: 913–924. 5. Roughan JE, Thorley-Lawson DA (2009) The intersection of Epstein-Barr virus with the germinal center. J Virol. 6. Crawford DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356: 461–473. 7. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA (1999) Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190: 567–576. 8. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, et al. (1993) Epstein- Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A 90: 8479–8483. 9. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM (1992) The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267: 24157–24160. 10. Kennedy G, Komano J, Sugden B (2003) Epstein-Barr virus provides a survival factor to Burkitt’s lymphomas. Proc Natl Acad Sci U S A 100: 14269–14274. 11. Lee JM, Lee KH, Weidner M, Osborne BA, Hayward SD (2002) Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis. Proc Natl Acad Sci U S A 99: 11878–11883. 12. Wang S, Rowe M, Lundgren E (1996) Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 56: 4610–4613. 13. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, et al. (1991) Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349: 612–614. 14. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, et al. (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65: 1107–1115. 15. Garibal J, Hollville E, Bell AI, Kelly GL, Renouf B, et al. (2007) Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A. J Virol 81: 7598–7607. 16. Altmann M, Hammerschmidt W (2005) Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3: e404. 17. Defrance T, Casamayor-Palleja M, Krammer PH (2002) The life and death of a B cell. Adv Cancer Res 86: 195–225. 18. Allday MJ (2009) How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma? Semin Cancer Biol 19: 366–376. 19. Kelly GL, Rickinson AB (2007) Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program. pp 277–284. 20. Kelly GL, Milner AE, Tierney RJ, Croom-Carter DS, Altmann M, et al. (2005) Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt’s lymphoma cells and with increased resistance to apoptosis. J Virol 79: 10709–10717. 21. Leao M, Anderton E, Wade M, Meekings K, Allday MJ (2007) Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt’s lymphoma cells. J Virol 81: 248–260. 22. Anderton E, Yee J, Smith P, Crook T, White RE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt’s lymphoma. Oncogene 27: 421–433. 23. Allday MJ, Sinclair A, Parker G, Crawford DH, Farrell PJ (1995) Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. Embo J 14: 1382–1391. 24. O’Nions J, Turner A, Craig R, Allday MJ (2006) Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 80: 12408–12413. 25. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, et al. (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5: e1000341. 26. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T (1991) p53 is frequently mutated in Burkitt’s lymphoma cell lines. Embo J 10: 2879–2887. 27. Speck SH (2002) EBV framed in Burkitt lymphoma. Nat Med 8: 1086–1087. 28. Kelly G, Bell A, Rickinson A (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8: 1098–1104. 29. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, et al. (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 183: 1957–1964. 30. O’Nions J, Allday MJ (2004) Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell- derived mitogens. J Gen Virol 85: 881–895. 31. White RE, Groves IJ, Turro E, Yee J, Kremmer E, et al. (2010) Extensive co- operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5: e13979. 32. Pearson GR, Luka J, Petti L, Sample J, Birkenbach M, et al. (1987) Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160: 151–161. 33. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, et al. (2010) Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog 6. 34. Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, et al. (2011) A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog 7: e1001294. 35. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3- only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053–1058. 36. Lindstrom MS, Wiman KG (2002) Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12: 381–387. 37. Tafani M, Minchenko DA, Serroni A, Farber JL (2001) Induction of the mitochondrial permeability transition mediates the killing of HeLa cells by staurosporine. Cancer Res 61: 2459–2466. 38. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL (2002) The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277: 16547–16552. 39. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5: 189–200. 40. Skalsky RL, Cullen BR (2010) Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64: 123–141. 41. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95: 8245–8250. 42. White RE, Calderwood MA, Whitehouse A (2003) Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demon- strates that the terminal repeats are required for both virus production and episomal persistence. J Gen Virol 84: 3393–3403. 43. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ (2002) Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A 99: 15036–15041. 44. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75: 7749–7755. 45. Finke J, Rowe M, Kallin B, Ernberg I, Rosen A, et al. (1987) Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt’s lymphoma and lymphoblastoid cell lines. J Virol 61: 3870–3878. 46. Inman GJ, Binne UK, Parker GA, Farrell PJ, Allday MJ (2001) Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol 75: 2400–2410. 47. Takada K, Horinouchi K, Ono Y, Aya T, Osato T, et al. (1991) An Epstein- Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5: 147–156. PLoS ONE | www.plosone.org 15 December 2011 | Volume 6 | Issue 12 | e28506